In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae.
The in vitro activities of iclaprim, a novel dihydrofolate reductase inhibitor, azithromycin, and levofloxacin were tested against 10 strains of Chlamydia trachomatis and 10 isolates of Chlamydia pneumoniae. For C. trachomatis and C. pneumoniae, the iclaprim MIC and minimal bactericidal concentration at which 90% of isolates were inhibited (MIC(90) and MBC(90)) were 0.5 micro g/ml, compared to an azithromycin MIC(90) and MBC(90) of 0.125 micro g/ml and levofloxacin MIC(90)s and MBC(90)s of 1 micro g/ml for C. trachomatis and 0.5 micro g/ml for C. pneumoniae.
Kohlhoff
S A
SA
Department of Pediatrics, Downstate Medical Center, State University of New York, Brooklyn, New York 11203-2098, USA. stephan.kohlhoff@downstate.edu
Roblin
P M
PM
Reznik
T
T
Hawser
S
S
Islam
K
K
Hammerschlag
M R
MR
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017963:Azithromycin / Q000494:pharmacology; D002690:Chlamydia Infections / Q000382:microbiology; D002692:Chlamydia trachomatis / Q000187:drug effects*; D016993:Chlamydophila pneumoniae / Q000187:drug effects*; D005493:Folic Acid Antagonists / Q000494:pharmacology*; D006801:Humans; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D005493:Folic Acid Antagonists; D011743:Pyrimidines; C486448:iclaprim; D064704:Levofloxacin; D017963:Azithromycin; D015242:Ofloxacin